Importance of Subtype Selectivity for Endothelin Receptor Antagonists in the Human Vasculature

  • Janet J. Maguire
  • Anthony P. Davenport


ET-1 acts via two receptors ETA and ETB. Many of the detrimental actions of ET-1 are mediated by ETA which predominates in smooth muscle of human vessels to cause vasoconstriction. Beneficial actions mediated by ETB include vasodilatation, clearing ET from the circulation, and promoting diuresis and natriuresis. Two classes of endothelin antagonist are currently in clinical use: ETA-selective and mixed antagonists that block both receptors. While ET antagonists have become established in the treatment of pulmonary arterial hypertension, the relative merit of the two classes continues to be debated. In order to classify antagonists as selective or mixed, it is important to have standardized measures of selectivity. This review compares endothelin receptor antagonist selectivity for compounds from different chemical classes measured in pharmacological assays using human tissue.


Pulmonary Arterial Hypertension Receptor Subtype Human Cardiovascular System Plasma Atrial Natriuretic Peptide Level Human Left Ventricle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Dr. Neil Davie for discussion, Mrs. Rhoda Kuc for critically reading the manuscript, and the British Heart Foundation (grant numbers PG/09/050/27734 and RG/10/077/28300) and an investigator initiated grant from Pfizer for support.


  1. 1.
    Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Hosoda K, Nakao K, Tamura N, et al. Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem. 1992;267:18797–804.PubMedGoogle Scholar
  4. 4.
    Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev. 2002;54:219–26.PubMedCrossRefGoogle Scholar
  7. 7.
    Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol. 2006;176(Pt 1):295–329.PubMedCrossRefGoogle Scholar
  8. 8.
    Palmer MJ. Endothelin receptor antagonists: status and learning 20 years on. Prog Med Chem. 2009;47:203–37.PubMedCrossRefGoogle Scholar
  9. 9.
    Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995;270:15262–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharmacol. 1999;126:391–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.PubMedCrossRefGoogle Scholar
  13. 13.
    Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev. 2006;24:63–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Galie N, Naeije R, Burgess G, Dilleen M. 3-year survival of patients treated with sitaxentan sodium (Thelin®) for pulmonary arterial hypertension. European Society of Cardiology, Barcelona, Spain; August 29–September 2, 2009.Google Scholar
  15. 15.
    Benza RL, Mehta S, Keogh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant. 2007;26:63–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2009;3:CD004434.PubMedGoogle Scholar
  17. 17.
    McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31:407–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Vachiery J-L, Davenport AP. The endothelin system in pulmonary and renal asculopathy – “Les liaisons dangereuses”. Eur Respir Rev. 2009;18:260–1.PubMedCrossRefGoogle Scholar
  20. 20.
    Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Eur J Clin Invest. 2009;39 Suppl 2:38–49.PubMedCrossRefGoogle Scholar
  21. 21.
    Dhaun N, Pollock DM, Goddard J, Webb DJ. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci. 2007;28:573–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1997;29:2–26.PubMedCrossRefGoogle Scholar
  23. 23.
    Karet FE, Davenport AP. Localization of endothelin peptides in human kidney. Kidney Int. 1996;49:382–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Karet FE, Kuc RE, Davenport AP. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993;44:36–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens. 2010;19:134–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Longaretti L, Benigni A. Endothelin receptor selectivity in chronic renal failure. Eur J Clin Invest. 2009;39 Suppl 2:32–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Neuhofer W, Pittrow D. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Invest. 2009;39 Suppl 2:50–67.PubMedCrossRefGoogle Scholar
  28. 28.
    Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109:1186–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Abraham D, Dashwood M. Endothelin-role in vascular disease. Rheumatology (Oxford). 2008;47 Suppl 5:23–4.CrossRefGoogle Scholar
  30. 30.
    Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. Endothelin receptor antagonism and cancer. Eur J Clin Invest. 2009;39 Suppl 2:74–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Bagnato A, Spinella F, Rosano L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol. 2008;86:473–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Growcott JW. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs. 2009;20:83–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Dickstein K, De Voogd HJ, Miric MP, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004;94:237–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003;25:317–40.PubMedGoogle Scholar
  35. 35.
    Tabrizchi R. SLV-306. Solvay. Curr Opin Investig Drugs. 2003;4:329–32.PubMedGoogle Scholar
  36. 36.
    Russell FD, Skepper JN, Davenport AP. Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme. Circ Res. 1998;83:314–21.PubMedGoogle Scholar
  37. 37.
    Maguire JJ, Davenport AP. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995;115:191–7.PubMedGoogle Scholar
  38. 38.
    Davenport AP, Maguire JJ. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci. 1994;15:9–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Love MP, Ferro CJ, Haynes WG, et al. Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res. 2000;47:166–72.PubMedCrossRefGoogle Scholar
  41. 41.
    Kiowski W, Luscher TF, Linder L, Buhler FR. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 1991;83:469–75.PubMedGoogle Scholar
  42. 42.
    Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994;368:703–10.PubMedCrossRefGoogle Scholar
  43. 43.
    Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Gasic S, Wagner OF, Vierhapper H, Nowotny P, Waldhausl W. Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol. 1992;19:176–80.PubMedCrossRefGoogle Scholar
  45. 45.
    Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol. 1996;119:311–4.PubMedGoogle Scholar
  46. 46.
    Davenport AP, Russell FD. Endothelin converting enzymes and endothelin receptor localisation in human tissues. Handb Exp Pharmacol. 2001;152:209–37.Google Scholar
  47. 47.
    Kuc RE, Karet FE, Davenport AP. Characterization of peptide and nonpeptide antagonists in human kidney. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S373–5.PubMedGoogle Scholar
  48. 48.
    Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000;105:925–33.PubMedCrossRefGoogle Scholar
  49. 49.
    Gandhi CR, Stephenson K, Olson MS. Endothelin, a potent peptide agonist in the liver. J Biol Chem. 1990;265:17432–5.PubMedGoogle Scholar
  50. 50.
    Pitts KR. Endothelin receptor antagonism in portal hypertension. Expert Opin Investig Drugs. 2009;18:135–42.PubMedCrossRefGoogle Scholar
  51. 51.
    Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996;241:233–40.CrossRefGoogle Scholar
  52. 52.
    Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol. 2004;2:1039–42.PubMedCrossRefGoogle Scholar
  53. 53.
    Reichen J, Gerbes AL, Steiner MJ, Sagesser H, Clozel M. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol. 1998;28:1020–30.PubMedCrossRefGoogle Scholar
  54. 54.
    Kojima H, Yamao J, Tsujimoto T, Uemura M, Takaya A, Fukui H. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol. 2000;32:43–50.PubMedCrossRefGoogle Scholar
  55. 55.
    Feng HQ, Weymouth ND, Rockey DC. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol. 2009;297:G27–33.PubMedCrossRefGoogle Scholar
  56. 56.
    Johnstrom P, Harris NG, Fryer TD, et al. [18F]-Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: radiosynthesis and in vivo imaging using microPET. Clin Sci. 2002;103 Suppl 48:4S–8.PubMedGoogle Scholar
  57. 57.
    Kelland NF, Kuc RE, McLean DL, et al. Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol. 2010;88:644–51.PubMedCrossRefGoogle Scholar
  58. 58.
    Bagnall AJ, Kelland NF, Gulliver-Sloan F, et al. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension. 2006;48:286–93.PubMedCrossRefGoogle Scholar
  59. 59.
    Maguire JJ, Johnson CM, Mockridge JW, Davenport AP. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle. Br J Pharmacol. 1997;122:1647–54.PubMedCrossRefGoogle Scholar
  60. 60.
    Maguire JJ, Davenport AP. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. Br J Pharmacol. 1998;125:238–40.PubMedCrossRefGoogle Scholar
  61. 61.
    Dive V, Chang CF, Yiotakis A, Sturrock ED. Inhibition of zinc metallopeptidases in cardiovascular disease–from unity to trinity, or duality? Curr Pharm Des. 2009;15:3606–21.PubMedCrossRefGoogle Scholar
  62. 62.
    Battistini B, Daull P, Jeng AY. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev. 2005;23:317–30.PubMedCrossRefGoogle Scholar
  63. 63.
    Kuc RE, Ashby MJ, Seed A, et al. The ECE/NEP inhibitor SLV306 (Daglutril), inhibits systemic endogenous conversion of infused big endothelin-1 in human volunteers. Proc Br Pharmacol Soc. 2005. doi:
  64. 64.
    Johnstrom P, Fryer TD, Richards HK, et al. Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver. Br J Pharmacol. 2010;159:812–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Naruse K, Naruse M, Watanabe Y, et al. Molecular form of immunoreactive endothelin in plasma and urine of normal subjects and patients with various disease states. J Cardiovasc Pharmacol. 1991;17 Suppl 7:S506–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Yanagisawa H, Hammer RE, Richardson JA, et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest. 2000;105:1373–82.PubMedCrossRefGoogle Scholar
  67. 67.
    D’Orleans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, Simard E. Endothelin-1 (1–31): from chymase-dependent synthesis to cardiovascular pathologies. Vasc Pharmacol. 2008;49:51–62.CrossRefGoogle Scholar
  68. 68.
    Fecteau MH, Honore JC, Plante M, Labonte J, Rae GA, D’Orleans-Juste P. Endothelin-1 (1–31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension. 2005;46:87–92.PubMedCrossRefGoogle Scholar
  69. 69.
    Maguire JJ, Kuc RE, Davenport AP. Vasoconstrictor activity of novel endothelin peptide, ET-1(1–31), in human mammary and coronary arteries in vitro. Br J Pharmacol. 2001;134:1360–6.PubMedCrossRefGoogle Scholar
  70. 70.
    O’Reilly G, Charnock-Jones DS, Morrison JJ, Cameron IT, Davenport AP, Smith SK. Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution. Biochem Biophys Res Commun. 1993;193:834–40.PubMedCrossRefGoogle Scholar
  71. 71.
    Plumpton C, Ashby MJ, Kuc RE, O’Reilly G, Davenport AP. Expression of endothelin peptides and mRNA in the human heart. Clin Sci. 1996;90(1):37–46.PubMedGoogle Scholar
  72. 72.
    Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992;10:1379–86.PubMedCrossRefGoogle Scholar
  73. 73.
    Matsumoto H, Suzuki N, Kitada C, Fujino M. Endothelin family peptides in human plasma and urine: their molecular forms and concentrations. Peptides. 1994;15:505–10.PubMedCrossRefGoogle Scholar
  74. 74.
    Bacon CR, Davenport AP. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol. 1996;117:986–92.PubMedGoogle Scholar
  75. 75.
    Chang I, Bramall, A, Baynash AG et al. Genetic study of ET-2 in mice. Eleventh international conference on endothelin, Montréal; 2009. p. 15.Google Scholar
  76. 76.
    Marciniak SJ, Plumpton C, Barker PJ, et al. Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmacol. 1992;5:175–82.PubMedCrossRefGoogle Scholar
  77. 77.
    Davenport AP, Hoskins SL, Kuc RE, Plumpton C. Differential distribution of endothelin peptides and receptors in human adrenal gland. Histochem J. 1996;28:779–89.PubMedCrossRefGoogle Scholar
  78. 78.
    Davenport AP, Kuc RE, Mockridge JW. Endothelin-converting enzyme in the human vasculature: evidence for differential conversion of big endothelin-3 by endothelial and smooth-muscle cells. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S1–3.PubMedCrossRefGoogle Scholar
  79. 79.
    Maguire JJ, Davenport AP. No alteration in vasoconstrictor endothelin-B-receptor density or function in human coronary artery disease. J Cardiovasc Pharmacol. 2000;36(5 Suppl 1):S380–1.PubMedGoogle Scholar
  80. 80.
    Halcox JP, Nour KR, Zalos G, Quyyumi AA. Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B. Hypertension. 2007;49:1134–41.PubMedCrossRefGoogle Scholar
  81. 81.
    McCulloch KM, Docherty CC, Morecroft I, MacLean MR. EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol. 1996;119:1125–30.PubMedGoogle Scholar
  82. 82.
    Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398–405.PubMedGoogle Scholar
  83. 83.
    Davenport AP, Kuc RE. Radioligand binding and molecular imaging techniques for the quantitative analysis of established and emerging orphan receptors systems. Methods Mol Biol. 2005;306:93–120.PubMedGoogle Scholar
  84. 84.
    Wu-Wong JR, Chiou WJ, Hoffman DJ, et al. Endothelins and endothelin receptor antagonists: binding to plasma proteins. Life Sci. 1996;58:1839–47.PubMedCrossRefGoogle Scholar
  85. 85.
    Williams Jr DL, Jones KL, Alves K, Chan CP, Hollis GF, Tung JS. Characterization of cloned human endothelin receptors. Life Sci. 1993;53:407–14.PubMedCrossRefGoogle Scholar
  86. 86.
    Molenaar P, O’Reilly G, Sharkey A, et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993;72:526–38.PubMedGoogle Scholar
  87. 87.
    Aramori I, Nirei H, Shoubo M, et al. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol. 1993;43:127–31.PubMedGoogle Scholar
  88. 88.
    Peter MG, Davenport AP. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart. Br J Pharmacol. 1996;117:455–62.PubMedGoogle Scholar
  89. 89.
    Peter MG, Davenport AP. Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol. 1995;114:297–302.PubMedGoogle Scholar
  90. 90.
    Doherty AM, Cody WL, He JX, et al. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol. 1993;22 Suppl 8:S98–102.PubMedCrossRefGoogle Scholar
  91. 91.
    Breu V, Loffler BM, Clozel M. In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. 1993;334:210–4.PubMedCrossRefGoogle Scholar
  92. 92.
    Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270:228–35.PubMedGoogle Scholar
  93. 93.
    Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem. 1997;40:1690–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Webb ML, Bird JE, Liu EC, et al. BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1995;272:1124–34.PubMedGoogle Scholar
  95. 95.
    Elliott JD, Lago MA, Cousins RD, et al. 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. J Med Chem. 1994;37:1553–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Johnstrom P, Fryer TD, Richards HK, et al. In vivo imaging of cardiovascular endothelin receptors using the novel radiolabelled antagonist [18F]-SB209670 and positron emission tomography (microPET). J Cardiovasc Pharmacol. 2004;44 Suppl 1:S34–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Patt WC, Edmunds JJ, Repine JT, et al. Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists. J Med Chem. 1997;40:1063–74.PubMedCrossRefGoogle Scholar
  98. 98.
    Maguire JJ, Kuc RE, Davenport AP. Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors. J Pharmacol Exp Ther. 1997;280:1102–8.PubMedGoogle Scholar
  99. 99.
    Walsh TF, Fitch KJ, Chakravarty PK, et al. The discovery of L-749329, a highly potent, orally active antagonist of endothelin receptors. Abstr Pap Am Chem Soc. 1994;298:145.Google Scholar
  100. 100.
    Fujimoto M, Mihara S, Nakajima S, Ueda M, Nakamura M, Sakurai K. A novel non-peptide endothelin antagonist isolated from bayberry, Myrica cerifera. FEBS Lett. 1992;305:41–4.PubMedCrossRefGoogle Scholar
  101. 101.
    Mihara S, Nakajima S, Matumura S, Kohnoike T, Fujimoto M. Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97–139. J Pharmacol Exp Ther. 1994;268(3):1122–8.PubMedGoogle Scholar
  102. 102.
    Davenport AP, O’Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol. 1995;114:1110–6.PubMedGoogle Scholar
  103. 103.
    Davenport AP, Kuc RE, Fitzgerald F, Maguire JJ, Berryman K, Doherty AM. [125I]-PD151242: a selective radioligand for human ETA receptors. Br J Pharmacol. 1994;111:4–6.PubMedGoogle Scholar
  104. 104.
    Maguire JJ, Bacon CR, Fujimoto M, Davenport AP. Myricerone caffeoyl ester (50–235) is a non-peptide antagonist selective for human ETA receptors. J Hypertens. 1994;12(6):675–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.University of Cambridge, Centre for Clinical Investigation, Addenbrooke’s HospitalCambridgeUK
  2. 2.Clinical Pharmacology UnitUniversity of Cambridge, Centre for Clinical Investigation, Addenbrooke’s HospitalCambridgeUK

Personalised recommendations